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The past 40 years have seen significant improvements in both event-free and overall sur-
vival for children with acute lymphoblastic and acute myeloid leukemia (ALL and AML,
respectively). Serial national and international clinical trials have optimized the use of con-
ventional chemotherapeutic drugs and, along with improvements in supportive care that
have enabled the delivery of more intensive regimens, have been responsible for the major
improvements in patient outcome seen over the past few decades. However, the bene-
fits of dose intensification have likely now been maximized, and over the same period,
the identification of new cytotoxic drugs has been limited. Therefore, challenges remain if
survival is to be improved further. In pediatric ALL, 5-year-survival rates of over 85% have
been achieved with risk-stratified therapy, but a notable minority of patients will still not
be cured. In pediatric AML, different challenges remain. A slower improvement in over-
all survival has taken place in this patient population. Despite the obvious morphological
heterogeneity of AML blasts, biological stratification is comparatively limited, and transla-
tion into risk-stratified therapeutic approaches has only best characterized by the use of
retinoic acid for t (15;17)-positive AML. Even where prognostic markers have been iden-
tified, limited therapeutic options or multi-drug resistance of AML blasts has limited the
impact on patient benefit. For both, the acute morbidities of current treatment remain sig-
nificant and may be life-threatening alone. In addition, the Childhood Cancer Survivor Study
(CCSS) highlighted many leukemia survivors develop one or more chronic medical condi-
tions attributable to treatment (1, 2). As the biology of leukemogenesis has become better
understood, key molecules and intracellular pathways have been identified that offer the
possibility of targeting directly the leukemia cells while sparing normal cells. Consequently,
there is now a drive to develop novel leukemia-specific or “targeted” therapies.These new
classes of drugs will have mechanisms of action, toxicities, and therapeutic indices quite
different from conventional cytotoxic drugs previously encountered, thus rendering current
clinical trial methodologies inappropriate. Clinical trial methods will need to be adapted to
accommodate these features of these new classes of drugs. This review will address the
challenges and some of the techniques for developing clinical trials for targeted therapies.
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CONVENTIONAL VERSUS TARGETED CHEMOTHERAPY –
WHAT’S THE DIFFERENCE?
For both ALL and AML, despite the diverse range of pharmaco-
logical drug classes in use (e.g. DNA alkylators, topoisomerase
inhibitors, antibiotics, steroids) treatment fundamentally revolves
around drugs which are cytotoxic, causing intracellular dam-
age that results in the death of leukemia blasts. The pre-clinical
rationale for these agents is determined through cytotoxicity
assays ex vivo and in vivo against whole populations of ALL or
AML cells. Side-effects of treatment may be substantial, including
severe myelosuppression, gastrointestinal, and neurological toxi-
city because of the non-selective mechanisms of cell killing. To
manage these toxicities, conventional chemotherapy is frequently
administered in cycles with gaps where no treatment is delivered,
so as to allow recovery of healthy tissue cell numbers and function.
Broadly, a successful drug leads to the eradication or substantial
reduction in leukemia cell burden to a state of minimal residual
disease (during therapy) or complete remission (CR) (at the end
of therapy).
Different principles apply for targeted therapies: targeted ther-
apies are aimed at pathways that function predominantly in
leukemic cells, ideally with absent or minimal function in healthy
tissues. Such pathways may be initiated by cell surface receptors
(CD33, CD22), specific intracellular kinases (FLT-3; BCR-ABL);
proteins regulating cell death (bcl-2 family), and modulators of
gene expression (histone demethylases). In contrast to conven-
tional cytotoxics, which are screened in whole cell assays, these
agents may initially be identified using target molecule libraries
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or by rational molecular engineering, based on understanding of
target molecule structure.
In turn, levels of target molecules or pathway function may
be measurable in leukemia cells as biomarkers for patient selec-
tion or disease response. The ability to measure leukemia response
to targeted therapy is particularly important, as binding of a
targeted drug to its intended molecule may not directly induce
cell death but cause other changes in cell function (e.g. mat-
uration with retinoic acid in PML-RaR AML) or be cytosta-
tic. As a result, the best dose-scheduling may not be deter-
mined by leukemia cell death but by efficacy against the target
molecule – an optimal biological dose (OBD). Daily uninter-
rupted dosing over long time periods, instead of traditional
“cycles” might prove to be the most appropriate method of admin-
istration, thus presenting further challenges to traditional early
phase trial designs.
DESIGNING CLINICAL TRIALS FOR TARGETED AGENTS
Clinical trials of drugs for any malignancy including leukemia have
followed the traditional phase I, II, and III approach in which the
primary outcomes of toxicity, disease response, and improvements
in survival, respectively, are evaluated. In this section, the chal-
lenges of using this pathway to evaluate novel targeted therapies
will be examined.
IDENTIFYING A SAFE DOSE
Phase I dose-finding trials are performed following the comple-
tion of pre-clinical investigations, to identify a tolerable dose,
which can be taken forward into a phase II trial to determine
drug activity. The process has been based on the assumption of
monotonic increasing dose–toxicity and dose–activity relation-
ships. The primary objective of phase I trials is to identify the
maximum tolerated dose (MTD), which is the highest safe dose
that is believed to be the most efficacious for eradication of malig-
nant cells. For hematological malignancies, phase I studies are
conventionally performed on patients with relapsed or refractory
childhood leukemias for whom there are no alternative therapies
that might lead to cure. The rarity of the disease and the success of
primary treatment protocols ensure that the numbers of patients
eligible for phase I studies is extremely small.
The starting dose is pediatric phase I trials is often based on
adult data, with 80% of the adult phase II dose, a commonly
used starting point. Often, the dose levels to be evaluated are pre-
specified. Doses could be escalated, with a 30% increase over the
prior dose level, as a typical increment. In some cases, the dose
escalation may continue beyond the adult phase II dose because of
the different pharmacokinetics and safety profile in children (3).
Toxicity within trials is assessed according to predefined systems
such as the NCI CTCAE Version 4.0.
There are two main classes of phase I dose-finding designs,
namely, the rule-based algorithms such as the 3+ 3 and its varia-
tions (3, 4), which include rolling-6 and the accelerated titration
design, and the model-based designs. In the conventional and most
widely used traditional 3+ 3 design, patients start at the lowest
dose levels based on pre-clinical or adult data, dependant on the
trial age group, in cohorts of three patients. If no patients expe-
rience dose-limiting toxicity (DLT) at that drug dose, the next
cohort will be given the next higher dose. If a DLT is observed in
one out of three patients, three additional patients will be treated
at the current dose. The MTD is defined as the highest dose level
where fewer than two out of six patients experience DLT.
In the “rolling six” design, enrollment may continue even when
three patients have entered a dose cohort (4). If there is no DLT in
the first three patients, then the fourth patient can be allocated to
the next higher dose level. If toxicity data are not available on the
first three patients, or if one DLT is observed, in which case the new
patient would be kept at the same dose level. If two or more DLTs
are observed in a single cohort, the dose level is decreased. The
main advantage of the design over the 3+ 3 design is the reduc-
tion of the overall trial duration as it aims to decrease the number
of times the trial is suspended to accrual (4, 5). However, this
trial design may also lead to more patients than necessary being
recruited at lower, perhaps inefficacious, dose levels than a 3+ 3
design. An alternative to the rule-based algorithms are the model-
based designs, such as the continual reassessment method (CRM).
Data accrued are continuously used to predict the dose level at
which DLT is likely to be reached, based on Bayesian or likelihood
modeling for the CRM (6, 7). The MTD is defined as the dose level
with a pre-determined toxicity probability, usually in the 15–40%
range. Although recently utilized in adult hematology drug devel-
opment trials, the use of the CRM design has not been extended to
pediatric leukemia studies (8). One example of the application of
CRM is in a study to evaluate a targeted anti-apoptosis inhibitor
(navitoclax, BH3 mimetic, and BCl2 inhibitor) in adult chronic
lymphoblastic leukemia (CLL). The study used a small popula-
tion of patients (n= 29), analogous to typical pediatric studies,
and the drug was given daily over a relatively long period of time
(median 7 months, range 1–>29 months). This study illustrates
how pediatric trial consortia could develop this model (9). A new
radionucleotide therapy for pediatric osteosarcoma (Samarium-
153-EDTMP) has already been tested using this trial design (10).
The Pediatric Brain Tumor Consortium has also used a modified
CRM to evaluate a gamma-secretase inhibitor (NOTCH pathway)
in CNS tumors (11). Despite higher statistical complexities, such
model-based designs have demonstrated superior operating char-
acteristics in terms of correctly identifying the right dose to take
forward to a phase II trial and allocating more patients to the MTD
than rule-based 3+ 3 designs (12, 13). Moreover, the sample size
required for such designs to have a satisfactory performance is usu-
ally less than the maximum sample size that is required for a 3+ 3
design. However, rule-based designs are still very appealing as they
are very simple, easy to implement in practice, and do not require
any specialist software or programing. Hence, they are still com-
monly used in practice. Nevertheless, in recent years, model-based
adaptive designs are gaining in popularity as researchers are made
more aware of their advantages and there is increasing availability
of software to implement such designs.
Both the rule-based algorithms and model-based designs
described so far assume that as the dose of drug is increased, the
activity (i.e., effect on leukemia cell death) increases, and there will
be a corresponding increase in toxicity to healthy tissues. As such,
toxicity is judged to act as a correlate for drug effect. This assump-
tion is reasonable for conventional cytotoxic chemotherapy in
pediatric leukemias. A retrospective analysis of 85 children treated
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for ALL at a single center on MRC UKALL protocols between 1973
and 1990, revealed an 18% improvement in relapse-free survival
when the dose of 6-MP was increased toward the 6-MP MTD, and
dose increases on average of 22% were achieved (14). Analyses of
POG studies (POG 8101, 8498, 8821, 9421) have similarly shown
that increasing the dose intensification of cytarabine toward the
MTD results in improvement in survival for children with AML
(15). For targeted agents, however, the relationship between target
effect and toxicity may not be linear, and hence require different
strategies for phase I studies. Targeted agents may be essentially
safe within the therapeutic dose range. They do not induce toxicity
in healthy tissues and hence the effects on non-malignant tissues
cannot be used as a marker of drug efficacy. Furthermore, targeted
agents may have a plateau in effect, meaning a higher dose will not
improve patient benefit, although it might result in toxicity. There-
fore, the aim of the trial is not to identify the MTD, but the OBD
or most desirable dose, which can be defined as the most favorable
dose with acceptable toxicity and high efficacy. This requires the
model to not only select the most appropriate dose based solely
on toxicity but also to examine both toxicity and activity.
Though there is an increasing use of targeted agents in drug
development in oncology, there are very limited statistical models
that have been developed to utilize both toxicity and activity to
obtain OBD. The pioneers in this field include Thall and Cook
who developed EffTox, Zhang, Sargent, and Mandrekar who pro-
posed an extension of the CRM-TriCRM, and a recent paper by
Hoering et al. on the use of a 3-arm modified selection design (16–
18). Very few of such designs have been implemented in practice,
partly due to difficulty in defining a suitable activity endpoint for
assessing targeted agents (which will be discussed later), as well as
the complexity of such designs (19). Others have proposed more
efficient models to measure overall severity of multiple types and
grades of adverse events, after considering that targeted agents
tend to induce multiple moderate toxicities rather than a binary
end point of DLT that is used conventionally (20).
Data from a number of adult and pediatric trials illustrate that
even a well engineered targeted agent may exhibit “off-target”
toxicity for a number reasons including non-specific binding,
pathway homology, and previously unknown expression of the
target molecule in healthy tissues.
Examples of such unexpected toxicity are found for all classes of
novel targeted agents. Gemtuzumab ozogamicin (GO), is an anti-
CD33 antibody conjugated to calicheamicin toxin and was given
accelerated FDA approval for the treatment of relapsed AML in
older patients not suitable for more intensive therapy. GO became
one of the few newly licensed therapies for AML in decades and was
assumed to offer a high degree of specificity since CD33 expres-
sion is limited to myeloid cells. However, in 2010, the drug was
voluntarily withdrawn because clinical trials suggested a lack of
improvement in overall survival and an excess of toxicity, includ-
ing veno-occlusive disease, which was unexpected based on the
molecule’s pre-clinical history and known mechanism of action
(15). Unexpected “off-target” toxicity has also been experienced
with another immunotherapy, engineered T cells. Here, T cells
designed to have high affinity for a MAGE-A3 epitope expressed
on myeloma and melanoma cells were found to cross-react with an
epitope on the protein titin, leading to fatal cardiomyopathy (21).
Previous studies and pre-clinical investigations had not predicted
the likelihood of this toxicity (22, 23). Small molecule enzyme
inhibitors have also demonstrated unexpected toxicities. Experi-
ence with tyrosine-kinase inhibitors (TKIs) illustrate that toxicities
cannot be assumed to be similar even if structurally related drugs
have been rationally derived. The small molecule TKI sunitinib
(c-kit, flt-3,VEGFR2, PDGFR-beta inhibition) is noted to have car-
diac toxicity as a DLT in a pediatric solid tumor phase I study, while
sorafenib (c-kit, flt-3, VEGFR2, PDGFR-beta, and RaF-pathway
inhibition) has completed phase I testing in children with leukemia
without this toxicity (24, 25). Therefore, investigators should be
aware that toxicities from novel targeted agents may be unexpected
and more varied, compared to conventional chemotherapy.
An alternative approach for appraisal of novel agents may be to
incorporate phase 0 studies into the drug development pathway.
These studies expose a small number of patients to a low dose
and duration of the drug and provide limited data on toxicity and
bioactivity. Although phase 0 studies have been performed success-
fully for targeted agents in adults with hematological malignancies,
none have yet been reported for children with leukemias (26).
A further challenge provided by conventional phase I trial
design is that toxicity is assessed in a relatively short time frame
after drug administration. Although short-term toxicities are
important, some targeted drugs are likely to be beneficial over
a continuous, longer maintenance period, potentially for years,
but no mechanism exists for assessing long-term toxicity within
current early phase strategies. Trials, which allow dose escalation
based on acute toxicity, may well underestimate or overlook signif-
icant dose-related side-effects that can occur after prolonged use
of targeted agents, particularly in the pediatric population where
physical growth and tissue maturation continues.
Alternative phase I trial designs that evaluate toxicities sec-
ondary to chronic use may be more relevant if the proposed use
of the targeted agent is long-term. Time-to-event CRM, tite-CRM
(27), offers an attractive advantage of allowing for late onset toxic-
ity to guide dose escalation, allowing the DLT observational period
to be much longer, for instance, for up to six treatment cycles. The
main idea of the tite-CRM is to estimate the dose–toxicity relation-
ship based on all the available DLT information, including those
patients who might not have completed their full DLT observa-
tional period, to guide the dose for the next patient. This will avoid
stopping the trial for a long period of time to assess DLT of the last
recruited patient. CRM has not yet been used for novel agent trials
in pediatric leukemias and could be more actively considered by
investigators and clinical trial consortia.
There is a limit to how much safety monitoring can be achieved
within the time constraint of a trial. Although short-term follow-
up of early phase clinical trial patients is commonly included in
protocol design (often 3–5 years) detailed long-term follow-up is
not. Such “late-effect” studies are frequently separate studies or
academically sponsored, and therefore, the long-term effects of
exposure to targeted agents is generally unknown. As many drugs
are tested on multiply relapsed patients who eventually die of dis-
ease within a relatively short time-span, the number of patients to
accrue meaningful data from is small. For those that survive,know-
ing which data are of relevance with targeted agents to capture
over the long-term is also unclear. Addressing this issue is difficult
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and requires concerted effort by drug companies, academia, and
regulatory agencies to report data.
The TKIs (imatinib mesylate, dasatinib, nilotinib, and bosu-
tinib) represent the paradigm of targeted therapies, in which
imatinib was identified in high-throughput screens to be an effec-
tive inhibitor of ABL kinase activity (28). In the COG phase I
trial of imatinib, eligible patients were treated with daily drug dos-
ing for 28 day cycles (median 6 cycles; range 1–46 cycles) (29).
The dose level was expanded to a maximum of six patients if one
had DLT during the first course. The MTD was defined as the level
immediately below the level at which two patients in a cohort of no
more than six had DLT. The drug was tolerated with mostly grade
1 and 2 gastrointestinal toxicities. There was only one episode of
first course DLT (grade 2 weight gain) and no MTD was defined.
However, in contrast to the trial study period patients, particu-
larly those with chronic myeloid leukemia, are treated with TKIs
for years. One retrospective study, in which children received a
median of 16.2 cycles of imatinib (range 31–83 cycles), far longer
than the median toxicity evaluation in the original phase I trials,
found significant growth retardation in pre-pubertal children.
Establishing a safe dose for targeted agents against pediatric
leukemias faces a number of challenges; not least the limited expe-
rience of using trial methodology other than traditional 3+ 3
phase I design. Investigators may need to use alternative endpoints
to toxicity, such as target inhibition or binding, drug concentra-
tions in the microenvironment (blood or bone marrow pharmaco-
kinetics) or biomarkers of activity (see next section) to determine
drug dosing and to make critical decisions on further investigation
of potentially active drugs.
MEASURING BIOLOGICAL EFFECT
Traditional pre-clinical testing has proposed therapeutic doses
and schedule for phase I trials, which then determine the rec-
ommended phase II dose based on toxicity. In the era of targeted
agents, a more appropriate end point would be the drug activity
against the target site, i.e., the OBD. This concept encroaches on the
traditional purpose of phase II studies. One challenge is therefore
to consider if phase I and II studies would better be combined for
targeted agents, so that a safe dose is rapidly identified but along-
side assessment of biological effect. In this section, the concept of
measuring effect on target pathways and phase II trial designs will
be discussed.
The objective for phase II trials is disease response, for example,
measured by clearance of blasts from the bone marrow, defined by
established criteria (30). For hematological malignancies access to
samples of malignant cells before, during, and after treatment is
readily available, through collection of malignant cells from blood
and bone marrow. Sensitive techniques are well-established and
include flow cytometry and PCR-based techniques to detect even
rare populations of leukemia cells. Therefore, for targeted agents
which are cytotoxic, alterations in phase II design may not be
needed. A recent phase II trial of the proteasome inhibitor, borte-
zomib, demonstrated an 80% CR and CR without platelet recovery
(CR+CRp, respectively) response rate in children with advanced
B-precursor ALL after a single course of treatment, with a signifi-
cant increase in overall survival compared to those patients whose
disease did not respond to this agent (31).
However, traditional cytotoxic endpoints may be invalid for
other classes of novel targeted agents. Plerixafor is a small molecule
antagonist to CXCR4 expressed on AML blasts, which prevents
binding to chemo-protective stromal cells. In an adult phase I/II
trial, no improvement in CR or overall survival was seen. How-
ever, a 2.5-fold increase in blast mobilization into the peripheral
blood was found, confirming biological activity at the dose level
tested (32). It is hypothesized that the liberation of cells into the
peripheral blood might improve efficacy for other drugs since the
cells would no longer enjoy the haven of the stromal protection.
Hence, this drug will need to be studied in combination with other
agents where dose sparing or increased efficacy might be achieved.
Further complexities exist when novel agents only target sub-
populations of blasts. Mutations may occur at different points of
blast evolution such that significant numbers of clones in a patient
will remain unaffected by the targeted therapy. Adding to this, there
is redundancy such that no single mutation is likely to be the only
driver for AML blast development in all cells. Assessment of the tar-
get activity of such drugs may well require sub-group or single-cell
assays in combination with genomic studies. Activating mutations
of FLT3, a receptor tyrosine kinase, have been identified in AML
and often occur late in AML development. FLT3 mutations have
been targeted by a number of small molecule inhibitors. A (phase
II) trial of lestaurtinib in combination with standard chemother-
apy for patients with relapsed AML expressing FLT3-activating
mutations had mixed outcomes (33). The majority of patients
achieved biological target effect, as measured by target FLT3 inhi-
bition. In turn, FLT3 inhibition correlated with CR and higher
plasma drug levels; however, there was no significant improve-
ment in remission rates or overall survival. Although high levels
of drug toxicity but did not correlate with FLT3 inhibition in vivo.
A number of other possible explanations exist for these mixed
results including a failure to sustain plasma levels of study drug,
or binding of drug to plasma proteins reducing the free, active
drug. Therefore, even with patient selection to ensure relevant
target exists, a full understanding of both the underlying biology
and the pharmacodynamic interactions of the drug are needed in
the interpretation of trial results. Instead of measuring cell death
by morphological or molecular remission, “time-to”-endpoints,
such as progression-free survival, time to hematopoietic stem cell
transplant, or overall survival may be more suitable end points
for evaluation of targeted agents. However, the question of how
to design such studies with an appropriate control group to con-
firm study drug activity remains difficult. Many have argued that
the use of historical control is only appropriate in settings when
there is no standard treatment, presence of well-established his-
torical control data (especially if it is recent), very low response
rates in the standard treatment, or if the study population is very
limited, which renders an extra arm of patients undergoing the
control treatment to be infeasible. Otherwise, historical controls
or hypothetical standardized survival times are often unreliable,
and a randomized trial with a control arm is important to provide
robust preliminary data to inform future phase III trials (34).
Several frequentist and Bayesian single and multi-stage phase
II single arm designs have been developed for binary endpoints
(35, 36). In single stage designs, a pre-specified drug response rate
is evaluated on a pre-determined number of patients based on the
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required statistical power of the predicted effect. The disadvantage
is that all subjects have to be treated before a conclusion about
drug effect can be made, thus potentially exposing children to the
unnecessary risk of ineffective new agents. For ethical reasons,
Simon’s two-stage designs and comparable Bayesian’s multi-stage
designs which allow for interim evaluation for futility to over-
come limitations are commonly used (37). Here, the goal is to
use a small number of patients to determine drug activity, and
the trial is terminated early if activity criteria are not met. Such
design offers the opportunity to prevent too many patients from
exposure to an inactive study drug. As the number of novel agents
grows this design could also allow the relatively small pool of
relapsed/refractory leukemia patients to be eligible for a number
of studies. Although one can evaluate time-to-event endpoints
as a binary outcome, for example, progression-free survival at 6
months (simply as a proportion of all subjects who survive at
the required time-point), this will, however, give a biased and an
inefficient estimate of the survival probability if the follow-up
periods are incomplete. Case and Morgan developed a more effi-
cient two-stage design for evaluation of time-to-event outcomes,
incorporating all the survival information up to the time-point of
interest (38).
A further challenge in evaluating new targeted agents is the
improbability that a single agent will be effective. In acute
leukemia, leukemogenesis arises from multiple, overlapping, bio-
logical pathways. It seems likely, therefore, that blasts might be
resistant to highly targeted agents. Further, because these drugs
are being tested in heavily pre-treated patients, the question of
whether the biology of leukemias in such patients is representa-
tive of leukemias in newly diagnosed patients arises, and further
complicates the evaluation of efficacy.
Ideally, novel drugs would be tested in untreated patients, but
the excellent cure rate for many leukemias and the desire not
to delay established treatment makes this approach unpalatable.
Indeed, the introduction of the new classes of drugs into routine
first line therapy will require a major reappraisal of the concept
and conduct of phase III studies, possibly including the notion that
achieving the same cure rate but with less toxicity is a worthy goal.
In certain instances, for instance, very high-risk patients where
the outcome using conventional therapies is poor, or where a clear,
treatable target exists, such as BCR-ABL, phase II window studies
may be a better approach, so that targeted agents would be assessed
in an initial “window” before conventional treatment starts. To
date, this notion has been little used in pediatric leukemias. A
single example has been a phase II window study of single-agent
rituximab for children with newly diagnosed B-non-Hodgkin’s
lymphoma (B-NHL) (39). The study successfully evaluated the
response rate of rituximab in chemo-naïve patients; importantly
no increase in relapse rate was seen despite the delay in starting
conventional therapy.
Phase II multi-arm strategies are an increasingly attractive, effi-
cient approach to evaluating more than one novel treatment in
a single trial. In these studies, patients are initially randomized
between a control standard of care arm and a number of differ-
ent novel drugs. All drugs are only evaluated against the control
arm and not against each other. Multi-arm study design does not
answer the challenges of selecting a suitable endpoint for novel
agents but has a number of advantages. It is highly flexible and
allows new drugs to be added at any time within the trial time-
line by protocol amendment, and speeds up the number of drugs
able to be tested in a limited pool of patients. The first part of
the study ensures unpromising treatments are dropped, and those
with potential efficacy continue to be tested. For a drug to proceed,
it must show a pre-determined degree of efficacy against selected
outcome measures (CR rates or surrogate markers) compared to
control. The design incorporates a minimal, clinically relevant dif-
ference that is large between novel drug and control arm such that
drugs that do not show activity are dropped early on. Promising
agents can then be taken forward for full evaluation in a ran-
domized controlled phase III trial, where the crucial question of
whether the new agent brings additional benefit over standard
therapy can be addressed. The design is also advantageous as a
fixed number of control patients can be used to compare against
patients on other arms, thus reducing the number of patients and
trial costs required per study drug in comparison to two arm stud-
ies. This “Pick a Winner” approach has not been used for pediatric
leukemia studies but has been used to good effect to test a number
of new targeted agents for AML in an elderly adult population
(40). Further design permutations have been statistically modeled
including combining a Simon two-stage design followed by a play-
the-winner approach (screened selection design, SSD), although
not yet implemented into clinical practice (41).
There is also scope to further explore Bayesian methods to
evaluate how information from adult leukemia trials can inform
pediatric trials with appropriate use of pharmacodynamics and
pharmacokinetic data in phase II trials. This is particularly useful,
if there are already completed trials on the targeted agents in the
same adult population. Methods to consider dynamic borrowing
of historical adult data, where the amount of weight assigned to
the historical adult data depends on how consistent it is with the
observed trial data on children could be explored (42).
PHASE III CHALLENGES
It could be said that current treatment strategies for both AML
and ALL have evolved to the point where patients either have an
excellent or a negligible chance of cure and that these two groups
can be defined very early in the course of the disease and therapy,
either by pretreatment factors such as cytogenetic of molecular
genetic factors or by response to therapy as assessed by minimal
residual disease. It has already been noted that patients with a
poor chance of cure with current therapy might be better served
by enrollment into phase II window studies, where early exposure
to a novel drug might lead to improved efficacy compared to the
conventional regimen or later exposure to the novel drug. A far
greater challenge is the development of a phase III trial method
that will allow incorporation of novel drugs into a conventional
regimen, presumably substituting for one or more of the conven-
tional drugs included in the standard regimen, since addition of a
new agent to an already successful regimen – where EFS may well
already be in excess of 95% – is unlikely to yield any improvement
in cure rate. The goal in this setting would likely be equivalence,
although a reduction in treatment related mortality might mean
that experimental treatment group had, in fact, a better outcome
than the conventional group. The problems here are the need for
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large numbers of patients, especially given that the multiplicity
of biological factors means ever-increasing sub-groups of smaller
size, and how to determine which of the conventional drugs should
be omitted.
ETHICAL DILEMMAS IN TARGETED AGENT TRIALS
The majority of early phase clinical trials for pediatric hematolog-
ical malignancies take place on patients with multiple relapses or
refractory disease. For researchers, trials are aimed at evaluating
novel drug toxicity and efficacy. For patients, and particularly their
families, the main driver for entry onto a drug trial is a hope that
the study drug will contribute to a cure, even against all odds. Fur-
ther complexity is added as research legislation in Europe and the
US appropriately consider children as vulnerable patients who are
dependent on a responsible adult to make decisions in their best
interest. However, a number of studies have identified that par-
ents with children enrolled on oncology trials have only a limited
understanding of the research aims and the risks of treatment, but
perceived that the trial drug would be of benefit in terms of their
child’s probability of cure (43–45). Therefore, both standard and
targeted agent trials share the significant challenge to explain ade-
quately the purpose of early phase trials,which may offer no benefit
to an individual patient or conversely induce toxicity with no anti-
leukemia activity. Consenting doctors involved in the process of
obtaining informed consent may also have conflicting roles as both
the patient’s primary physician and study investigator.
CONCLUSION
Although the development of intensive multi-agent chemother-
apy regimens, with concomitant advances in supportive care have
led to major improvements in outcome for children with acute
leukemia, particularly of the lymphoid and also of the myeloid
type, treatment related toxicity and mortality, together with a
persisting problem of treatment failure in a small but significant
minority of patients means that further developments in treatment
are needed. It is likely that the major improvements in outcomes
seen in the 1980s through to the early 2000s, arose as a consequence
of dose intensification, and further improvements by this avenue
will not be attained. Thus, the time is ripe for the introduction of
new classes of “biological” agents. Current models for phase I and
II studies may well not be appropriate for these types of drugs.
Thus, the notion of the MTD and the need for a separate assess-
ment of efficacy may be supplanted by a single study combining
the identification of an OBD with confirmation of expected target
pathway efficacy.
In the longer term, the need for better therapy of identifiable
high-risk groups will necessitate the development of phase II win-
dow studies. These studies, together with the hybrid phase I/II
OBD studies, may give some notion about which conventional
drugs in a standard regimen can be substituted by novel drugs with
at least equal efficacy but much improved safety. The ultimate goal
should be the use of a rationally tailored combination of biological
agents based on knowledge of the leukemogenic events for each
individual patient. This approach will lead to some very novel and
challenging problems in trial design, where sub-group sizes will
be very small – perhaps only 10’s or even fewer patients – and the
expected outcome will be that all patients are cured.
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